Stromal galectin-1 expression is associated with long-term survival in resectable pancreatic ductal adenocarcinoma

References

• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62:10 - 29; http://dx.doi.org/10.3322/caac.20138; PMID: 22237781
   PubMed Web of Science ®Google Scholar
• Stathis A, Moore MJ. Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol 2010; 7:163 - 72; http://dx.doi.org/10.1038/nrclinonc.2009.236; PMID: 20101258
   PubMed Web of Science ®Google Scholar
• Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, et al, Groupe Tumeurs Digestives of Unicancer, PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364:1817 - 25; http://dx.doi.org/10.1056/NEJMoa1011923; PMID: 21561347
   PubMed Web of Science ®Google Scholar
• Adham M, Jaeck D, Le Borgne J, Oussoultzouglou E, Chenard-Neu MP, Mosnier JF, et al. Long-term survival (5-20 years) after pancreatectomy for pancreatic ductal adenocarcinoma: a series of 30 patients collected from 3 institutions. Pancreas 2008; 37:352 - 7; http://dx.doi.org/10.1097/MPA.0b013e31818166d2; PMID: 18665012
   PubMed Web of Science ®Google Scholar
• Bradley EL 3rd. Long-term survival after pancreatoduodenectomy for ductal adenocarcinoma: the emperor has no clothes?. Pancreas 2008; 37:349 - 51; http://dx.doi.org/10.1097/MPA.0b013e31818e9100; PMID: 18953246
   PubMed Web of Science ®Google Scholar
• Cleary SP, Gryfe R, Guindi M, Greig P, Smith L, Mackenzie R, et al. Prognostic factors in resected pancreatic adenocarcinoma: analysis of actual 5-year survivors. J Am Coll Surg 2004; 198:722 - 31; http://dx.doi.org/10.1016/j.jamcollsurg.2004.01.008; PMID: 15110805
   PubMed Web of Science ®Google Scholar
• Conlon KC, Klimstra DS, Brennan MF. Long-term survival after curative resection for pancreatic ductal adenocarcinoma. Clinicopathologic analysis of 5-year survivors. Ann Surg 1996; 223:273 - 9; http://dx.doi.org/10.1097/00000658-199603000-00007; PMID: 8604907
   PubMed Web of Science ®Google Scholar
• Han SS, Jang JY, Kim SW, Kim WH, Lee KU, Park YH. Analysis of long-term survivors after surgical resection for pancreatic cancer. Pancreas 2006; 32:271 - 5; http://dx.doi.org/10.1097/01.mpa.0000202953.87740.93; PMID: 16628082
   PubMed Web of Science ®Google Scholar
• Mosca F, Giulianotti PC, Balestracci T, Di Candio G, Pietrabissa A, Sbrana F, et al. Long-term survival in pancreatic cancer: pylorus-preserving versus Whipple pancreatoduodenectomy. Surgery 1997; 122:553 - 66; http://dx.doi.org/10.1016/S0039-6060(97)90128-8; PMID: 9308613
   PubMed Web of Science ®Google Scholar
• Reddy S, Wolfgang CL, Cameron JL, Eckhauser F, Choti MA, Schulick RD, et al. Total pancreatectomy for pancreatic adenocarcinoma: evaluation of morbidity and long-term survival. Ann Surg 2009; 250:282 - 7; http://dx.doi.org/10.1097/SLA.0b013e3181ae9f93; PMID: 19638918
   PubMed Web of Science ®Google Scholar
• Riall TS, Cameron JL, Lillemoe KD, Winter JM, Campbell KA, Hruban RH, et al. Resected periampullary adenocarcinoma: 5-year survivors and their 6- to 10-year follow-up. Surgery 2006; 140:764 - 72; http://dx.doi.org/10.1016/j.surg.2006.04.006; PMID: 17084719
   PubMed Web of Science ®Google Scholar
• Schnelldorfer T, Ware AL, Sarr MG, Smyrk TC, Zhang L, Qin R, et al. Long-term survival after pancreatoduodenectomy for pancreatic adenocarcinoma: is cure possible?. Ann Surg 2008; 247:456 - 62; http://dx.doi.org/10.1097/SLA.0b013e3181613142; PMID: 18376190
   PubMed Web of Science ®Google Scholar
• Shimada K, Sakamoto Y, Nara S, Esaki M, Kosuge T, Hiraoka N. Analysis of 5-year survivors after a macroscopic curative pancreatectomy for invasive ductal adenocarcinoma. World J Surg 2010; 34:1908 - 15; http://dx.doi.org/10.1007/s00268-010-0570-9; PMID: 20376443
   PubMed Web of Science ®Google Scholar
• Finks JF, Osborne NH, Birkmeyer JD. Trends in hospital volume and operative mortality for high-risk surgery. N Engl J Med 2011; 364:2128 - 37; http://dx.doi.org/10.1056/NEJMsa1010705; PMID: 21631325
   PubMed Web of Science ®Google Scholar
• Garcea G, Dennison AR, Pattenden CJ, Neal CP, Sutton CD, Berry DP. Survival following curative resection for pancreatic ductal adenocarcinoma. A systematic review of the literature. JOP 2008; 9:99 - 132; PMID: 18326920
   PubMedGoogle Scholar
• Kim R, Tan A, Lai KK, Jiang J, Wang Y, Rybicki LA, et al. Prognostic roles of human equilibrative transporter 1 (hENT-1) and ribonucleoside reductase subunit M1 (RRM1) in resected pancreatic cancer. Cancer 2011; 117:3126 - 34; http://dx.doi.org/10.1002/cncr.25883; PMID: 21264835
   PubMed Web of Science ®Google Scholar
• Carpelan-Holmström M, Nordling S, Pukkala E, Sankila R, Lüttges J, Klöppel G, et al. Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the Finnish Cancer Registry. Gut 2005; 54:385 - 7; http://dx.doi.org/10.1136/gut.2004.047191; PMID: 15710987
   PubMed Web of Science ®Google Scholar
• Jørgensen MT, Fenger C, Klöppel G, Lüttges J. Long-term survivors among Danish patients after resection for ductal adenocarcinoma of the pancreas. Scand J Gastroenterol 2008; 43:581 - 3; http://dx.doi.org/10.1080/00365520701834943; PMID: 18415751
   PubMed Web of Science ®Google Scholar
• D’Angelica M, Brennan MF, Suriawinata AA, Klimstra D, Conlon KC. Intraductal papillary mucinous neoplasms of the pancreas: an analysis of clinicopathologic features and outcome. Ann Surg 2004; 239:400 - 8; PMID: 15075659
   PubMed Web of Science ®Google Scholar
• Maire F, Hammel P, Terris B, Paye F, Scoazec JY, Cellier C, et al. Prognosis of malignant intraductal papillary mucinous tumours of the pancreas after surgical resection. Comparison with pancreatic ductal adenocarcinoma. Gut 2002; 51:717 - 22; http://dx.doi.org/10.1136/gut.51.5.717; PMID: 12377813
   PubMed Web of Science ®Google Scholar
• Raimondo M, Tachibana I, Urrutia R, Burgart LJ, DiMagno EP. Invasive cancer and survival of intraductal papillary mucinous tumors of the pancreas. Am J Gastroenterol 2002; 97:2553 - 8; http://dx.doi.org/10.1111/j.1572-0241.2002.06022.x; PMID: 12385438
   PubMed Web of Science ®Google Scholar
• Allen PJ. Pancreatic adenocarcinoma: putting a hump in survival. J Am Coll Surg 2007; 205:Suppl S76 - 80; http://dx.doi.org/10.1016/j.jamcollsurg.2007.06.331; PMID: 17916524
   PubMedGoogle Scholar
• Pan S, Chen R, Stevens T, Bronner MP, May D, Tamura Y, et al. Proteomics portrait of archival lesions of chronic pancreatitis. PLoS One 2011; 6:e27574; http://dx.doi.org/10.1371/journal.pone.0027574; PMID: 22132114
   PubMed Web of Science ®Google Scholar
• Pan S, Chen R, Reimel BA, Crispin DA, Mirzaei H, Cooke K, et al. Quantitative proteomics investigation of pancreatic intraepithelial neoplasia. Electrophoresis 2009; 30:1132 - 44; http://dx.doi.org/10.1002/elps.200800752; PMID: 19373808
   PubMed Web of Science ®Google Scholar
• Dennis G Jr., Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, et al. DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol 2003; 4:3; http://dx.doi.org/10.1186/gb-2003-4-5-p3; PMID: 12734009
   PubMed Web of Science ®Google Scholar
• Huang W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009; 4:44 - 57; http://dx.doi.org/10.1038/nprot.2008.211; PMID: 19131956
   PubMed Web of Science ®Google Scholar
• Chen R, Pan S, Brentnall TA, Aebersold R. Proteomic profiling of pancreatic cancer for biomarker discovery. Mol Cell Proteomics 2005; 4:523 - 33; http://dx.doi.org/10.1074/mcp.R500004-MCP200; PMID: 15684406
   PubMed Web of Science ®Google Scholar
• Chen R, Brentnall TA, Pan S, Cooke K, Moyes KW, Lane Z, et al. Quantitative proteomics analysis reveals that proteins differentially expressed in chronic pancreatitis are also frequently involved in pancreatic cancer. Mol Cell Proteomics 2007; 6:1331 - 42; http://dx.doi.org/10.1074/mcp.M700072-MCP200; PMID: 17496331
   PubMed Web of Science ®Google Scholar
• Daroqui CM, Ilarregui JM, Rubinstein N, Salatino M, Toscano MA, Vazquez P, et al. Regulation of galectin-1 expression by transforming growth factor beta1 in metastatic mammary adenocarcinoma cells: implications for tumor-immune escape. Cancer Immunol Immunother 2007; 56:491 - 9; http://dx.doi.org/10.1007/s00262-006-0208-9; PMID: 16900348
   PubMed Web of Science ®Google Scholar
• Spano D, Russo R, Di Maso V, Rosso N, Terracciano LM, Roncalli M, et al. Galectin-1 and its involvement in hepatocellular carcinoma aggressiveness. Mol Med 2010; 16:102 - 15; http://dx.doi.org/10.2119/molmed.2009.00119; PMID: 20200618
   PubMed Web of Science ®Google Scholar
• Zhong LP, Wei KJ, Yang X, Pan HY, Ye DX, Wang LZ, et al. Overexpression of Galectin-1 is negatively correlated with pathologic differentiation grade in oral squamous cell carcinoma. J Cancer Res Clin Oncol 2010; 136:1527 - 35; http://dx.doi.org/10.1007/s00432-010-0810-2; PMID: 20157731
   PubMed Web of Science ®Google Scholar
• Chen R, Yi EC, Donohoe S, Pan S, Eng J, Cooke K, et al. Pancreatic cancer proteome: the proteins that underlie invasion, metastasis, and immunologic escape. Gastroenterology 2005; 129:1187 - 97; http://dx.doi.org/10.1053/j.gastro.2005.08.001; PMID: 16230073
   PubMed Web of Science ®Google Scholar
• Camby I, Le Mercier M, Lefranc F, Kiss R. Galectin-1: a small protein with major functions. Glycobiology 2006; 16:137R - 57R; http://dx.doi.org/10.1093/glycob/cwl025; PMID: 16840800
   PubMed Web of Science ®Google Scholar
• Bian CF, Zhang Y, Sun H, Li DF, Wang DC. Structural basis for distinct binding properties of the human galectins to Thomsen-Friedenreich antigen. PLoS One 2011; 6:e25007; http://dx.doi.org/10.1371/journal.pone.0025007; PMID: 21949831
   PubMedGoogle Scholar
• Rubinstein N, Alvarez M, Zwirner NW, Toscano MA, Ilarregui JM, Bravo A, et al. Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; A potential mechanism of tumor-immune privilege. Cancer Cell 2004; 5:241 - 51; http://dx.doi.org/10.1016/S1535-6108(04)00024-8; PMID: 15050916
   PubMed Web of Science ®Google Scholar
• Thijssen VL, Barkan B, Shoji H, Aries IM, Mathieu V, Deltour L, et al. Tumor cells secrete galectin-1 to enhance endothelial cell activity. Cancer Res 2010; 70:6216 - 24; http://dx.doi.org/10.1158/0008-5472.CAN-09-4150; PMID: 20647324
   PubMed Web of Science ®Google Scholar
• Thijssen VL, Poirier F, Baum LG, Griffioen AW. Galectins in the tumor endothelium: opportunities for combined cancer therapy. Blood 2007; 110:2819 - 27; http://dx.doi.org/10.1182/blood-2007-03-077792; PMID: 17591944
   PubMed Web of Science ®Google Scholar
• Gál P, Vasilenko T, Kostelníková M, Jakubco J, Kovác I, Sabol F, et al. Open Wound Healing In Vivo: Monitoring Binding and Presence of Adhesion/Growth-Regulatory Galectins in Rat Skin during the Course of Complete Re-Epithelialization. Acta Histochem Cytochem 2011; 44:191 - 9; http://dx.doi.org/10.1267/ahc.11014; PMID: 22096259
   PubMed Web of Science ®Google Scholar
• Bhowmick NA, Neilson EG, Moses HL. Stromal fibroblasts in cancer initiation and progression. Nature 2004; 432:332 - 7; http://dx.doi.org/10.1038/nature03096; PMID: 15549095
   PubMed Web of Science ®Google Scholar
• Chu GC, Kimmelman AC, Hezel AF, DePinho RA. Stromal biology of pancreatic cancer. J Cell Biochem 2007; 101:887 - 907; http://dx.doi.org/10.1002/jcb.21209; PMID: 17266048
   PubMed Web of Science ®Google Scholar
• De Wever O, Demetter P, Mareel M, Bracke M. Stromal myofibroblasts are drivers of invasive cancer growth. Int J Cancer 2008; 123:2229 - 38; http://dx.doi.org/10.1002/ijc.23925; PMID: 18777559
   PubMed Web of Science ®Google Scholar
• De Wever O, Mareel M. Role of tissue stroma in cancer cell invasion. J Pathol 2003; 200:429 - 47; http://dx.doi.org/10.1002/path.1398; PMID: 12845611
   PubMed Web of Science ®Google Scholar
• Iozzo RV. The family of the small leucine-rich proteoglycans: key regulators of matrix assembly and cellular growth. Crit Rev Biochem Mol Biol 1997; 32:141 - 74; http://dx.doi.org/10.3109/10409239709108551; PMID: 9145286
   PubMed Web of Science ®Google Scholar
• Cui X, Song B, Hou L, Wei Z, Tang J. High expression of osteoglycin decreases the metastatic capability of mouse hepatocarcinoma Hca-F cells to lymph nodes. Acta Biochim Biophys Sin (Shanghai) 2008; 40:349 - 55; http://dx.doi.org/10.1111/j.1745-7270.2008.00392.x; PMID: 18401533
   PubMed Web of Science ®Google Scholar
• Rucci N, Rufo A, Alamanou M, Capulli M, Del Fattore A, Ahrman E, et al. The glycosaminoglycan-binding domain of PRELP acts as a cell type-specific NF-kappaB inhibitor that impairs osteoclastogenesis. J Cell Biol 2009; 187:669 - 83; http://dx.doi.org/10.1083/jcb.200906014; PMID: 19951916
   PubMed Web of Science ®Google Scholar
• Holcomb B, Yip-Schneider M, Schmidt CM. The role of nuclear factor kappaB in pancreatic cancer and the clinical applications of targeted therapy. Pancreas 2008; 36:225 - 35; http://dx.doi.org/10.1097/MPA.0b013e31815b3207; PMID: 18362834
   PubMed Web of Science ®Google Scholar